Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Indivior PLC
  6. News
  7. Summary
    INDV   GB00BRS65X63

INDIVIOR PLC

(INDV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Indivior : Financial Document

11/16/2021 | 02:36am EST

Indivior PLC

Jefferies London Healthcare Conference November 16, 2021

Forward-looking statements

This announcement contains certain statements that are forward-looking. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from those expressed or implied in such statements because they relate to future events. Forward-looking statements include, among other things, statements regarding the Indivior Group's financial guidance for 2021 and its medium- and long- term growth outlook, its operational goals, its product development pipeline and statements regarding ongoing litigation and other statements containing the words "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions.

Various factors may cause differences between Indivior's expectations and actual results, including, among others (including those described in the risk factors described in the most recent Indivior PLC Annual Report and in subsequent releases): factors affecting sales of Indivior Group's products and financial position; the outcome of research and development activities; decisions by regulatory authorities regarding the Indivior Group's drug applications or authorizations; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved, if at all; the outcome of post-approval clinical trials; competitive developments; difficulties or delays in manufacturing and in the supply chain; disruptions in or failure of information technology systems; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; challenges in the commercial execution; claims and concerns that may arise regarding the safety or efficacy of the Indivior Group's products and product candidates; risks related to legal proceedings, including compliance with the Indivior Group's agreements with the U.S. Department of Justice and with the Office of Inspector General of the Department of Health and Human Services, non-compliance with which could result in potential exclusion from participating in U.S. Federal health care programs; the ongoing investigative and antitrust litigation matters; the opioid national multi-district litigation and securities class action litigation; the Indivior Group's ability to protect its patents and other intellectual property; the outcome of patent infringement litigation relating to Indivior Group's products, including the ongoing ANDA lawsuits; changes in governmental laws and regulations; issues related to the outsourcing of certain operational and staff functions to third parties; risks related to the evolving COVID-19 pandemic and the potential impact of COVID-19 on the Indivior Group's operations and financial condition, which cannot be predicted with confidence; uncertainties related to general economic, political, business, industry, regulatory and market conditions; and the impact of acquisitions, divestitures, restructurings, internal reorganizations, product recalls and withdrawals and other unusual items.

Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.

2

Why Indivior?

Pioneering life-transforming treatments for addiction and serious mental illness Strong cash generation + financial position to fuel growth ($1 bn of cash)

Visible progress with further upside potential from multiple growth drivers

3

Indivior - the basics

TTM Net Revenue

(Sept. 30, 2021)

Key Facts

25%

$753m

75%

US

Rest of World

Global leader in medication-assisted treatment (MAT) for opioid use disorder (OUD)

No. 1 position in largest market (U.S.) for >15 years

Direct presence in >40 countries, with operations in Canada, Europe and Australia

Profitable w/ ~$1bn of cash to fuel strategy

+27%

TTM net revenue growth

$187m

TTM adj. operating profit

$200m

YTD cash flow from ops.

800+ highly-engaged employees

4

Three approved treatments for growing disease spaces

Key Product Descriptions

U.S. Patient Prevalence

Market

Annual NR

& Market Growth

Position

Goal

L

A

I

  • Long-actinginjectable (buprenorphine extended-release) for moderate to severe opioid use disorder (OUD)

~3.0 mil. patients(1) No. 1

$1bn+

Mid- to high-single digits

(s)

Risperidone extended-release

~2.5 mil. patients(2) Emerging

$200m to

Mid- to high-single

$300m

injection to treat schizophrenia

digits

Oral film medication (buprenorphine

and naloxone) taken daily to treat opioid dependence

  1. Symphony Health Analytica and Indivior analytics
  2. Source: Treatment Advocacy Center; "Schizophrenia - Fact Sheet"

~3.0 mil. patients(1) ~20%

N.A.

(of daily

Mid- to high-singlemarket) digits

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Indivior plc published this content on 16 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 November 2021 07:35:03 UTC.


ę Publicnow 2021
All news about INDIVIOR PLC
01/12FDA flags risk of dental issues from use of opioid addiction drug buprenorphine
RE
2021Biogen V. Mylan Written Description - What Does The Federal Circuit's Decision Really M..
AQ
2021INDIVIOR : to Present New Data on Buprenorphine Extended-Release at the 2021 Joint Interna..
PU
2021INDIVIOR : Financial Document
PU
2021Scopia Capital Sells 3% Stake In Indivior
MT
2021Scopia Capital Management To Sell 3% Stake In Indivior
MT
2021Indivior Presents Modelling Data on Interaction Between Buprenorphine and Fentanyl in O..
PU
2021Indivior to Participate in Upcoming November 2021 Healthcare Investor Conferences
PU
2021Indivior Presents Study at the 2021 National Correctional Health Care Conference on Fac..
PU
2021Indivior's Lifts FY21 Net Revenue Guidance As Q3 Earnings Rise
MT
More news
Analyst Recommendations on INDIVIOR PLC
More recommendations
Financials (USD)
Sales 2021 758 M - -
Net income 2021 159 M - -
Net cash 2021 708 M - -
P/E ratio 2021 15,2x
Yield 2021 -
Capitalization 2 129 M 2 124 M -
EV / Sales 2021 1,87x
EV / Sales 2022 1,66x
Nbr of Employees 788
Free-Float 98,8%
Chart INDIVIOR PLC
Duration : Period :
Indivior PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INDIVIOR PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 3,03 $
Average target price 4,11 $
Spread / Average Target 35,6%
EPS Revisions
Managers and Directors
Mark Crossley Executive Director, CEO & COO
Ryan Preblick Chief Financial Officer & Executive Director
Graham C. Hetherington Chairman
Christian Heidbreder Chief Scientific Officer
Cynthia Cetani Chief Compliance & Integrity Officer
Sector and Competitors
1st jan.Capi. (M$)
INDIVIOR PLC-12.53%2 124
MERCK KGAA-16.30%95 442
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD-13.94%36 092
KYOWA KIRIN CO. LTD.-6.99%13 770
SK BIOPHARMACEUTICALS CO., LTD.-14.51%5 601
BETTA PHARMACEUTICALS CO., LTD.-11.69%4 573